Sanofi - Aventis Groupe: Nirsevimab significantly protected

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy

Related Keywords

Japan , Tokyo , United States , Paris , France General , France , United Kingdom , Philadelphia , Pennsylvania , Langley , Northumberland , China , California , Ujiie , Tochigi , Illinois , Chicago , Eva Schaefer Jansen , Nicolas Obrist , Corentine Driancourt , William Muller , Felix Lauscher , Kate Conway , Ann Roberth Lurie , Nathalie Pham , Sandrine Guendoul , Sally Bain , Priya Nanduri , European Medicines Agency Priority , Nasdaq , Northwestern University Feinberg School Of Medicine , Global Head Of Research , Astrazeneca , California Perinatal Association , Burden Of Community , Japan Agency For Medical Research , Oxford Vaccines Group , China Center , Health Alert Network , Centers For Disease , Drug Administration , Community Trials , Regulatory Agency , National Medical Products Administration , Development Vaccines , Euronext , Thenew England Journal , New England Journal , Northwestern University Feinberg School , Scientific Director , Vice President , Collaboration Revenue , Breakthrough Therapy Designation , Drug Evaluation , European Medicines Agency , Promising Innovative Medicine , United Kingdom Medicines , Drug Selection , Promote New Drug Development , Japan Agency , Medical Research , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Healthy Late , Medically Attended , Healthy Late Preterm , Term Infants , Healthy Preterm , Single Dose Nirsevimab , Lung Disease , Medically Attended Respiratory Syncytial Virus , Lower Respiratory Track Infection , Syncytial Virus , California Perinatal , Accessed March , Respiratory Syncytial Virus Infections , Southern United , Disease Control , Intensive Care Units , Retrospectively Matched Cohort Study , Infection Control , Sanofi , Eventis , Roupe , Nirsevimab , Ignificantly , Protected , Infants , Against , Disease , Hase , Trial ,